Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), announced that Interim Chief Executive Officer Eric So will participate in a fireside chat at the Jefferies Global Healthcare Conference in New York. The discussion, scheduled for June 4, 2026, at 2:35 p.m. EDT, will be webcast live, with a replay available through the Events & Presentations section of the company’s investor relations website. This event provides a platform for Helus Pharma to communicate its strategic vision and clinical milestones to the investment community.
The company’s proprietary NSAs are synthetic molecules designed to activate serotonin pathways that are believed to promote neuroplasticity, addressing large unmet needs for individuals suffering from depression, anxiety, and other mental health conditions. Helus Pharma is currently developing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004, another proprietary NSA, is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, operates in Canada, the United States, the United Kingdom, and Ireland. The participation in the Jefferies conference is significant as it allows the company to showcase its leadership in the NSA space and its commitment to improving the treatment landscape for mental health conditions. The fireside chat will likely cover the progress of its clinical trials, the potential of its drug candidates, and the company's future direction. For more details, the full press release is available at https://ibn.fm/1QdP7.
